152 related articles for article (PubMed ID: 33768319)
1. TERT promoter mutation in sebaceous neoplasms.
Muñoz-Jiménez MT; Blanco L; Ruano Y; Carrillo R; Santos-Briz Á; Riveiro-Falkenbach E; Requena L; Kutzner H; Garrido MC; Rodríguez-Peralto JL
Virchows Arch; 2021 Sep; 479(3):551-558. PubMed ID: 33768319
[TBL] [Abstract][Full Text] [Related]
2. Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.
Harvey NT; Tabone T; Erber W; Wood BA
Pathology; 2016 Aug; 48(5):454-62. PubMed ID: 27311873
[TBL] [Abstract][Full Text] [Related]
3. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
Jessup CJ; Redston M; Tilton E; Reimann JD
Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
[TBL] [Abstract][Full Text] [Related]
4. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis.
Cornejo KM; Hutchinson L; Deng A; Tomaszewicz K; Welch M; Lyle S; Dresser K; Cosar EF
Hum Pathol; 2014 Jun; 45(6):1213-20. PubMed ID: 24767862
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
6. Clinico-pathological predictors of mismatch repair deficiency in sebaceous neoplasia: A large case series from a single Australian private pathology service.
Walsh MD; Jayasekara H; Huang A; Winship IM; Buchanan DD
Australas J Dermatol; 2019 May; 60(2):126-133. PubMed ID: 30506759
[TBL] [Abstract][Full Text] [Related]
7. Twenty-Eight Cases of Extraocular Sebaceous Carcinoma: A Correlative Clinicopathological and Immunohistochemical Analysis of Extraocular Sebaceous Carcinomas and Benign Sebaceous Gland Tumors.
Boecker W; Reusch M; Mielke V; Reusch U; Hallermann C; Loening T; Tiemann M; Buchwalow I
Am J Dermatopathol; 2021 Feb; 43(2):93-102. PubMed ID: 32568835
[TBL] [Abstract][Full Text] [Related]
8. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutations in periocular carcinomas: implications of ultraviolet light in pathogenesis.
Lin SY; Liao SL; Hong JB; Chu CY; Sheen YS; Jhuang JY; Tsai JH; Liau JY
Br J Ophthalmol; 2016 Feb; 100(2):274-7. PubMed ID: 26472403
[TBL] [Abstract][Full Text] [Related]
10. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma.
Campos MA; Macedo S; Fernandes M; Pestana A; Pardal J; Batista R; Vinagre J; Sanches A; Baptista A; Lopes JM; Soares P
J Am Acad Dermatol; 2019 Mar; 80(3):660-669.e6. PubMed ID: 30165166
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
[TBL] [Abstract][Full Text] [Related]
13. Loss of mismatch repair proteins in sebaceous gland tumors.
Popnikolov NK; Gatalica Z; Colome-Grimmer MI; Sánchez RL
J Cutan Pathol; 2003 Mar; 30(3):178-84. PubMed ID: 12641777
[TBL] [Abstract][Full Text] [Related]
14. Frequent TLE1 Expression in Cutaneous Neoplasms.
Xiong Y; Dresser K; Cornejo KM
Am J Dermatopathol; 2019 Jan; 41(1):1-6. PubMed ID: 30608261
[TBL] [Abstract][Full Text] [Related]
15. NGS Analysis Confirms Common
Peterson C; Moore R; Hicks JL; Morsberger LA; De Marzo AM; Zou Y; Eberhart CG; Campbell AA
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445161
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
17. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
Otsuji K; Sasaki T; Tanabe M; Seto Y
Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803
[TBL] [Abstract][Full Text] [Related]
18. Mutation profiles of follicular thyroid tumors by targeted sequencing.
Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
[TBL] [Abstract][Full Text] [Related]
19. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients.
Harwood CA; Swale VJ; Bataille VA; Quinn AG; Ghali L; Patel SV; Dove-Edwin I; Cerio R; McGregor JM
J Invest Dermatol; 2001 Feb; 116(2):246-53. PubMed ID: 11180000
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
